A CONTROLLED TRIAL OF METHYLPREDNISOLONE IN THE EMERGENCY TREATMENT OF ACUTE ASTHMA
A CONTROLLED TRIAL OF METHYLPREDNISOLONE IN THE EMERGENCY TREATMENT OF ACUTE ASTHMA
复制标题
DOI：
10.1056/nejm198601163140304
复制
发表时间：
1986-01-16
影响因子：
158.5
通讯作者：
GLUCK, EH
中科院分区：
文献类型：
--
作者：
LITTENBERG, B;GLUCK, EH
97例支气管哮喘急性发作患者入组了一项双盲、安慰剂对照、随机试验，在标准哮喘急诊治疗的基础上，在急诊室给予静脉注射甲泼尼龙（125 mg）。所有患者在进入研究时的哮喘严重程度的主观和肺量测定指数相似，但48例接受甲基强的松龙治疗的患者中只有9例（19%）需要住院，而对照组49例患者中有23例（47%）需要住院（P < 0.003）。我们的研究结果表明，在重症哮喘的紧急治疗中及时使用糖皮质激素可以预防显著的发病率，减少住院人数，并节省大量的医疗费用。
Ninety-seven acutely ill patients with bronchial asthma were enrolled in a double-blind, placebo-controlled, randomized trial of intravenous methylprednisolone (125 mg), given on presentation in the emergency room in addition to standard emergency treatments for asthma. Subjective and spirometric indexes of the severity of the asthma were similar on entry into the study in all patients, but only 9 of 48 patients (19 percent) treated with methylprednisolone required hospital admission, as compared with 23 of 49 patients (47 percent) in the control group (P < 0.003). Our results suggest that prompt use of glucocorticoids in the emergency treatment of severe asthma can prevent significant morbidity, reduce the number of hospitalizations, and effect substantial savings in health care costs.